Beximco Pharma appoints Quamrun Naher Ahmed and Reem Shamsuddoha to its Board as Non-Executive Directors

– BANGLADESH, Dhaka –  Beximco Pharmaceuticals Limited (LON: BXP), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announced the appointment of Quamrun Naher Ahmed and Reem Shamsuddoha to its Board as Non-Executive Directors, effective from 30 November 2020, subject to regulatory approvals.

About Quamrun Naher Ahmed

Ms. Quamrun Naher Ahmed, before she retired from service in the Bangladesh Government, worked in several different Government departments including Finance, Commerce, Shipping Fisheries and Livestock and Home Affairs. In January 2014, Ms Ahmed was appointed Additional Secretary: Financial Institutions Division, Ministry of Finance of the Government of the People’s Republic of Bangladesh. In March 2016, she was nominated as a Director of the Board of IFIC Bank Limited by the Ministry of Finance. Ms Ahmed is a member of the Executive, Risk Management and the Nomination and Remuneration Committees of the Board of Directors of IFIC Bank Limited. She is also the Chairman of IFIC Securities Limited, a Director of IFIC Money Transfer (UK) Limited and Nepal Bangladesh Bank Limited, Nepal.

About Reem Shamsuddoha

Ms. Reem Shamsuddoha has a background in e-commerce and marketing having been educated in Bangladesh and attended Gabelli School of Business, Fordham University in New York. She is VP at Dohatec New Media, an independent software vendor and technology firm developing solutions for clients in North America, Asia and Europe, as well as assisting in the rollout of E-Government procurement systems for four Government agencies in Bangladesh.

About Beximco Pharmaceuticals

Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company’s broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered-dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.

Beximco Pharma′s state-of-the-art manufacturing facilities are certified by global regulatory authorities of the USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 5,500 employees are driving the company towards achieving its aspiration to be among the most admired companies in the world.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.